

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/G779D37E24C4EN.html>

Date: February 2020

Pages: 99

Price: US\$ 2,000.00 (Single User License)

ID: G779D37E24C4EN

Abstracts

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H1 2020, provides an overview of the Granulomatosis with Polyangiitis (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Immunology) pipeline guide also reviews of key

players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 2, 1 and 4 respectively.

Granulomatosis with Polyangiitis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Immunology).

The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Granulomatosis with Polyangiitis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Overview

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Companies Involved in
Therapeutics Development

Biogen Inc

Bristol-Myers Squibb Co

ChemoCentryx Inc

Generium

GlaxoSmithKline Plc

Humanigen Inc

iBio Inc

InflaRx NV

Insmed Inc

Nichi-Iko Pharmaceutical Co Ltd

Pharmapraxix

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacopan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HGEN-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INS-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Product Development

Milestones

Featured News & Press Releases

Jan 30, 2020: The CHMP recommended extensions of indication for MabThera

Oct 09, 2019: Two new options for self-administration of NUCALA now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment

Sep 30, 2019: Roche's Rituxan secures approval for first paediatric indication

Jun 12, 2019: FDA grants priority review to Genentech's Rituxan (Rituximab) in children with two rare blood vessel disorders

May 16, 2019: GSK presents Nucala at ATS 2019

Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Dec 12, 2017: GSK Achieves Approval for Nucala (mepolizumab) for the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) for Adults in the US

Jun 28, 2017: GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Mar 25, 2014: NICE says yes to new treatment for rare autoimmune disease in final guidance

Feb 14, 2014: GSK announces start of Phase III study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis

Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera

Apr 19, 2011: Genentech Receives FDA Approval For Rituxan Plus Steroid For Use In Severe Forms Of Vasculitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Biogen Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by ChemoCentryx Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Generium, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by GlaxoSmithKline Plc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Humanigen Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by iBio Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by InflaRx NV, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Insmed Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline by Pharmapraxi, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Dormant Projects, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Biogen Inc

Bristol-Myers Squibb Co

ChemoCentryx Inc

Generium

GlaxoSmithKline Plc

Humanigen Inc

iBio Inc

InflaRx NV

Insmmed Inc

Nichi-Iko Pharmaceutical Co Ltd

Pharmapraxix

I would like to order

Product name: Granulomatosis with Polyangiitis (Wegener's Granulomatosis) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/G779D37E24C4EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G779D37E24C4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970